Editas Medicine Inc (EDIT) Insider Sells $512,079.25 in Stock
Editas Medicine Inc (NASDAQ:EDIT) insider Katrine Bosley sold 14,995 shares of the firm’s stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $34.15, for a total value of $512,079.25. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Katrine Bosley also recently made the following trade(s):
- On Friday, December 1st, Katrine Bosley sold 8,333 shares of Editas Medicine stock. The stock was sold at an average price of $29.58, for a total value of $246,490.14.
- On Wednesday, November 1st, Katrine Bosley sold 8,333 shares of Editas Medicine stock. The stock was sold at an average price of $23.64, for a total value of $196,992.12.
Shares of Editas Medicine Inc (EDIT) traded up $0.59 during midday trading on Thursday, hitting $33.92. The stock had a trading volume of 1,224,135 shares, compared to its average volume of 1,656,767. The company has a market cap of $1,500.00 and a PE ratio of -10.47. The company has a debt-to-equity ratio of 0.19, a current ratio of 10.12 and a quick ratio of 10.12. Editas Medicine Inc has a 12 month low of $13.12 and a 12 month high of $36.00.
Several analysts recently commented on EDIT shares. Barclays started coverage on Editas Medicine in a research note on Wednesday, September 6th. They set an “overweight” rating and a $28.00 price objective on the stock. ValuEngine upgraded Editas Medicine from a “sell” rating to a “hold” rating in a report on Saturday, September 30th. Morgan Stanley reiterated an “equal weight” rating and set a $28.00 target price (up previously from $27.00) on shares of Editas Medicine in a report on Friday, October 6th. Zacks Investment Research cut Editas Medicine from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Finally, Cowen reiterated a “buy” rating on shares of Editas Medicine in a report on Tuesday, November 7th. One analyst has rated the stock with a sell rating, six have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Editas Medicine has an average rating of “Hold” and an average price target of $26.73.
A number of large investors have recently modified their holdings of EDIT. State Street Corp lifted its stake in Editas Medicine by 305.4% in the 2nd quarter. State Street Corp now owns 537,640 shares of the company’s stock valued at $9,022,000 after purchasing an additional 405,022 shares during the last quarter. American Century Companies Inc. acquired a new stake in Editas Medicine in the 3rd quarter valued at about $7,497,000. Ark Investment Management LLC lifted its stake in Editas Medicine by 121.9% in the 2nd quarter. Ark Investment Management LLC now owns 510,187 shares of the company’s stock valued at $8,561,000 after purchasing an additional 280,265 shares during the last quarter. Northern Trust Corp lifted its stake in Editas Medicine by 245.9% in the 2nd quarter. Northern Trust Corp now owns 373,149 shares of the company’s stock valued at $6,261,000 after purchasing an additional 265,273 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Editas Medicine by 12.5% in the 2nd quarter. Vanguard Group Inc. now owns 2,177,146 shares of the company’s stock valued at $36,533,000 after purchasing an additional 241,973 shares during the last quarter. Institutional investors and hedge funds own 65.70% of the company’s stock.
Editas Medicine Company Profile
Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.